| Q49483419 | A multicenter, prospective study evaluating the impact of the clinical pharmacist-physician counselling on warfarin therapy management in Lebanon |
| Q33949244 | A review of the safety of anticoagulants in older people using the medicines management pathway: weighing the benefits against the risks |
| Q87478060 | Adherence to warfarin treatment among patients with atrial fibrillation |
| Q47713063 | Anticoagulation Control in Swiss Primary Care: Time in Therapeutic Range Percentages Exceed Benchmarks of Phase III Trials |
| Q98945570 | Anticoagulation Control of Warfarin in Pharmacist-Led Clinics Versus Physician-Led Clinics: A Prospective Observational Study |
| Q37620945 | Anticoagulation control among patients with nonvalvular atrial fibrillation: A single tertiary cardiac center experience |
| Q37047213 | Anticoagulation for the prevention of stroke in non-valvular AF in general practice: room for improvement |
| Q28315636 | Anticoagulation in atrial fibrillation |
| Q38689603 | Association Between Patient-Reported Medication Adherence and Anticoagulation Control |
| Q91577650 | Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation |
| Q90480727 | Associations between illness beliefs, medication beliefs, anticoagulation-related quality of life, and INR control: Insights from the Switching Study |
| Q37711462 | Atrial Fibrillation and Cardiovascular Comorbidities, Survival and Mortality: A Real-Life Observational Study |
| Q26799571 | Atrial fibrillation in Sub-Saharan Africa: epidemiology, unmet needs, and treatment options |
| Q36679380 | CHADS2 Score is a Poor Predictor of Non-cerebral Acute Arterial Occlusion in Patients with Non-valvular Atrial Fibrillation |
| Q36101603 | Can We Predict Individual Combined Benefit and Harm of Therapy? Warfarin Therapy for Atrial Fibrillation as a Test Case |
| Q34157446 | Challenges and opportunities for developing and implementing incentives to improve health-related behaviors in older adults |
| Q38372780 | Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation |
| Q47140605 | Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation |
| Q35196123 | Comorbidities against quality control of VKA therapy in non-valvular atrial fibrillation: a French national cross-sectional study |
| Q45139213 | Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials |
| Q93123794 | Cost of Healthcare Associated With Deep Vein Thrombosis in Patients Treated With Warfarin in Turkey: 2010-2013 Database Analysis of a Tertiary Care Center |
| Q36064839 | Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses |
| Q43677955 | Could geriatric characteristics explain the under-prescription of anticoagulation therapy for older patients admitted with atrial fibrillation? A retrospective observational study. |
| Q37960511 | Current challenges in personalizing warfarin therapy |
| Q37069336 | Developing a Complex Educational-Behavioural Intervention: The TREAT Intervention for Patients with Atrial Fibrillation |
| Q33553902 | Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) |
| Q37877168 | Drug-related problems identified in post-discharge medication reviews for patients taking warfarin. |
| Q45819770 | Economic evaluation of a randomized controlled trial of pharmacist-supervized patient self-testing of warfarin therapy |
| Q38525918 | Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view |
| Q38412381 | Edoxaban, a Novel Oral Factor Xa Inhibitor |
| Q24202280 | Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation |
| Q24234691 | Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation |
| Q36335405 | Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. |
| Q21132512 | Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial |
| Q34134664 | Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial |
| Q38386998 | Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation. |
| Q89565785 | Factors Influencing 1-Year Medication Adherence of Korean Ischemic Stroke Survivors |
| Q36527615 | Factors affecting the quality of anticoagulation with warfarin: experience of one cardiac centre |
| Q39309926 | HAS-BLED Predicts Warfarin Control in Australian Patients treated for Deep Vein Thrombosis |
| Q34141211 | Implications of the CHA2DS2-VASc and HAS-BLED Scores for Thromboprophylaxis in Atrial Fibrillation |
| Q33837185 | Implications of using different methods to characterise anticoagulant control in patients with second generation mechanical heart valve prostheses |
| Q53123110 | Inter-individual differences in baseline coagulation activities and their implications for international normalized ratio control during warfarin initiation therapy. |
| Q26991728 | Managing anticoagulation for atrial fibrillation: current issues and future strategies |
| Q33795571 | Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review |
| Q38389058 | Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation. |
| Q37495909 | New Stroke Prophylaxis Options in Atrial Fibrillation Patients |
| Q47135998 | Non-valvular atrial fibrillation: impact of apixaban on patient outcomes |
| Q38972270 | Overcoming global challenges in stroke prophylaxis in atrial fibrillation: The role of non-vitamin K antagonist oral anticoagulants |
| Q44714275 | Patient selection for the implantation of a left atrial appendage occluder in primary and secondary prevention of cardioembolic stroke in atrial fibrillation |
| Q38942817 | Percent Time in Range with Warfarin as a Performance Measure: How Long a Sampling Frame Is Needed? |
| Q96128348 | Poor Time in Therapeutic Range Control is Associated with Adverse Clinical Outcomes in Patients with Non-Valvular Atrial Fibrillation: A Report from the Nationwide COOL-AF Registry |
| Q94544639 | Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables |
| Q58099349 | Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review |
| Q37885792 | Prediction of stroke risk in atrial fibrillation, prevention of stroke in atrial fibrillation, and the impact of long-term monitoring for detecting atrial fibrillation |
| Q26866343 | Prevention of cardioembolic stroke |
| Q37843742 | Quality measures and benchmarking for warfarin therapy |
| Q48533036 | Quality of Anticoagulation With Warfarin at a Tertiary Hospital in Botswana. |
| Q57086707 | Quality of INR Control and Outcomes Following Venous Thromboembolism |
| Q38666184 | Quality of Pharmacist-Managed Anticoagulation Therapy in Long-Term Ambulatory Settings: A Systematic Review |
| Q37278238 | Quality of anticoagulation control among patients with atrial fibrillation: An experience of a tertiary care center in Saudi Arabia |
| Q42923266 | Quality of anticoagulation control in atrial fibrillation |
| Q35629873 | Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy |
| Q47823178 | Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry. |
| Q40762447 | Relationship between time spent at extreme International Normalized Ratios and time in therapeutic range with bleeding and thrombosis in warfarin-treated patients |
| Q41808456 | Results from the Registry of Atrial Fibrillation (AFABE): Gap between Undiagnosed and Registered Atrial Fibrillation in Adults--Ineffectiveness of Oral Anticoagulation Treatment with VKA. |
| Q35553343 | Risk of bleeding and stroke with oral anticoagulation and antiplatelet therapy in patients with atrial fibrillation in Taiwan: a nationwide cohort study |
| Q38221812 | Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence |
| Q57179093 | State of play and future direction with NOACs: An expert consensus |
| Q38080912 | Stop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature review |
| Q37469069 | Stroke And Bleeding Risk Assessment: Where Are We Now? |
| Q28359631 | Stroke Prevention in Atrial Fibrillation: Focus on Latin America |
| Q36168742 | Stroke and Bleeding Risk Associated With Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation in Clinical Practice |
| Q38244278 | Stroke and bleeding risk in atrial fibrillation: navigating the alphabet soup of risk-score acronyms (CHADS2 , CHA2 DS2 -VASc, R2 CHADS2 , HAS-BLED, ATRIA, and more). |
| Q37780750 | Stroke prevention in atrial fibrillation patients |
| Q37945342 | Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation. |
| Q33582706 | TRial of an Educational intervention on patients' knowledge of Atrial fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT). |
| Q92087148 | The Effect of Demographic Factors and VKORC1 1639 G>A Genotypes on Estimated Warfarin Maintenance Dose in Iranian Patients Under Warfarin Therapy |
| Q92941461 | The SAMe-TT2R2 Score Predicts Warfarin Control in an Australian Population with Atrial Fibrillation |
| Q37812378 | The assessment of stroke and bleeding risk in atrial fibrillation: where are we now? |
| Q37666333 | The business case for quality improvement: oral anticoagulation for atrial fibrillation |
| Q33848923 | The clinical impact of different coagulometers on patient outcomes |
| Q38097972 | The hidden costs of anticoagulation in hospitalized patients with non-valvular atrial fibrillation |
| Q45883878 | The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation |
| Q34200428 | The quality of warfarin prescribing and monitoring in Veterans Affairs nursing homes |
| Q44676772 | Therapeutic management of non-valvular atrial fibrillation. Update 2013 |
| Q38655829 | Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies. |
| Q38812464 | Use of direct oral anticoagulants in patients with nonvalvular atrial fibrillation according to clinical profile |
| Q36017218 | Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation |
| Q30766944 | Warfarin treatment among Finnish patients with atrial fibrillation: retrospective registry study based on primary healthcare data |
| Q85334978 | [Scope of the latest RE-LY substudies: clinical implications] |